Ignite Creation Date:
2024-05-06 @ 7:54 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06188650
Status:
RECRUITING
Last Update Posted:
2024-01-03
First Post:
2023-12-18
Brief Title:
The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization DEB-BACE Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC a Prospective Single Arm Single Center Exploratory Clinical Study
Sponsor:
Ningbo Medical Center Lihuili Hospital
Organization:
Ningbo Medical Center Lihuili Hospital
Study Overview
Official Title:
The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization DEB-BACE Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC a Prospective Single Arm Single Center Exploratory Clinical Study
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to learn about Drug loaded microspheres for bronchial artery chemoembolization DEB-BACE combined with anlotinib and adebelimumab in patients with advanced NSCLC after second-line treatment
The main question it aims to answer is
The efficacy and safety of Drug Loading Beads Bronchial Arterial Chemoembolization DEB-BACE combined with Anlotinib and Adebelimumab in the third line treatment of advanced NSCLC
Participants will receive DEB-BACE treatment rest for 1 week and then undergo 1 cycle of treatment with combination of Anlotinib and Adebelimumab With a maximum of 4 DEB-BACE treatments depending on the therapeutic effect followed by continued treatment with Anlotinib and Adebelimumab
The main question it aims to answer is
The efficacy and safety of Drug Loading Beads Bronchial Arterial Chemoembolization DEB-BACE combined with Anlotinib and Adebelimumab in the third line treatment of advanced NSCLC
Participants will receive DEB-BACE treatment rest for 1 week and then undergo 1 cycle of treatment with combination of Anlotinib and Adebelimumab With a maximum of 4 DEB-BACE treatments depending on the therapeutic effect followed by continued treatment with Anlotinib and Adebelimumab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None